Mechanisms of Action of Levetiracetam and Newer SV2A Ligands

Blue Books of Neurology

Volumn 33, Issue C, 2009, Pages 27-38

  Klitgaard, Henrik ^a   Matagne, Alain ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84989336460     PISSN: 1877184X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-1-4160-6171-7.00003-0     Document Type: Chapter

References (38)

1. Gower, A, Noyer, M, Verloes, R, Gobert, J, Wülfert, E, ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol 222 (1992), 193–203.
2. Klitgaard, H, Matagne, A, Gobert, J, Wülfert, E, Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 353 (1998), 191–206.
3. Klitgaard, H, Verdru, P, Levetiracetam: the first SV2A ligand for the treatment of epilepsy. Expert Opin on Drug Discov 2 (2007), 1537–1545.
4. Klitgaard, H, Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?. Epilepsia 42:suppl 4 (2001), 13–18.
5. Löscher, W, Hönack, D, Rundfeldt, C, Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 284 (1998), 474–479.
6. Stratton, S, Large, C, Cox, B, Davies, G, Hagan, R, Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model. Epilepsy Res 53 (2003), 95–106.
7. Silver, JM, Shin, C, McNamara, JO, Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilepsy. Ann Neurol 29 (1991), 356–363.
8. Lamberty, Y, Margineanu, D, Klitgaard, H, Absence of negative impact of levetiracetam on cognitive function and memory in normal and amygdala-kindled rats. Epilepsy Behav, 2000, 333–342.
9. Margineanu, DG, Klitgaard, H, Levetiracetam mechanisms of action. Levy, RH, Mattson, RH, Meldrum, BS, Perucca, E, (eds.) Antiepileptic Drugs, 5th, 2002;, Lippincott Williams & Wilkins, Philadelphia, 419–427.
10. Margineanu, DG, Klitgaard, H, Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res 42:4 (2000), 281–285.
11. Niespodziany, I, Klitgaard, H, Margineanu, DG, Desynchronizing effect of levetiracetam on epileptiform responses in rat hippocampal slices. Neuroreport 14:9 (2003), 1273–1276.
12. Hans, G, Nguyen, L, Rocher, V, Belachew, S, Moonen, Matagne, A, Klitgaard, H, Levetiracetam: no relevant effect on ionotropic excitatory glutamate receptors. Epilepsia, 41(Suppl 7), 2000, 35.
13. Carunchio, I, Pieri, M, Ciotti, MT, Albo, F, Zona, C, Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug levetiracetam. Epilepsia 48:4 (2007), 654–662.
14. Rigo, JM, Hans, G, Nguyen, L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 136:5 (2002), 659–672.
15. Coulter, DA, Mossy fiber zinc and temporal lobe epilepsy: pathological association with altered “epileptic” gamma-aminobutyric acid A receptors in dentate granule cells. Epilepsia 41:Suppl 6 (2000), S96–S99.
16. +) current in pyramidal neurons of rat hippocampal slices. Neurosci Lett 306:1-2 (2001), 5–8.
17. Pisani, A, Bonsi, P, Martella, G, et al. Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. Epilepsia 45:7 (2004), 719–728.
18. Lukyanetz, EA, Shkryl, VM, Kostyuk, PG, Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 43:1 (2002), 9–18.
19. + transients and epileptiform potentials in hippocampal neurons. Neuroreport 14:3 (2003), 471–475.
20. +] increase induced by ATP and bradykinin in PC12 cells. J Pharmacol Exp Ther 313:2 (2005), 720–730.
21. Noyer, M, Gillard, M, Matagne, A, Henichart, JP, Wülfert, E, The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 286:2 (1995), 137–146.
22. Lynch, BA, Lambeng, N, Nocka, K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 101:26 (2004), 9861–9866.
23. Crowder, KM, Gunther, JM, Jones, TA, et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci U S A 96:26 (1999), 15268–15273.
24. + regulators in neurotransmitter release. Neuron 24:4 (1999), 1003–1016.
25. Leclercq K, Dassesse D, Lambeng N, Klitgaard H, Matagne A. Unaltered seizure susceptibility contrasts accelerated kindling acquisition in heterozygous SV2A KO mice. Program No. 82.7 2006, Abstract viewer/itinerary planner. Washington DC, Society for Neurosciences 2006. On-line.
26. Matagne, A, Kenda, B, Michel, PH, Klitgaard, H, ucb 34714, a new pyrrolidone derivative: comparison with levetiracetam in animal models of chronic epilepsy in vivo. Epilepsia, 44(suppl 9), 2003, 261.
27. Wasterlain, C, Suchomelova, L, Matagne, A, Klitgaard, H, Mazarati, A, Shinmei, S, Baldwin, R, Brivaracetam is a potent anticonvulsant in experimental status epilepticus. Epilepsia, 46(suppl 8), 2005, 219.
28. Margineanu, D, Kenda, B, Michel, Ph, Matagne, A, Klitgaard, H, ucb 34714, a new pyrrolidone derivative: comparison with levetiracetam in hippocampal slice epilepsy models in vitro. Epilepsia, 44(suppl 9), 2003, 261.
29. Gillard M, Fuks B, Lambeng N, Chatelain P, Matagne A. Binding characteristics of brivaracetam, a novel antiepileptic drug candidate. Program No.3.186. 2007 Abstract Viewer. Philadelphia, PA: American Epilepsy Society.
30. Rigo, JM, Nguyen, L, Hans, G, et al. ucb 34714: effect on inhibitory and excitatory neurotransmission. Epilepsia, 45(suppl 3), 2004, 56.
31. Kostyuk, PG, Lukyanetz, EA, Klitgaard, H, Margineanu, DG, ucb 34714, a new pyrrolidone derivative, without impact on high- and low-voltage activated calcium currents in rat isolated neurons. Epilepsia 45:suppl 7 (2004), 141–142.
32. + currents in rat cortical neurons in culture. Epilepsia, 45(suppl 7), 2004, 146.
33. Matagne, A, Margineanu, DG, Michel, Ph, Kenda, B, Klitgaard, H, Seletracetam (ucb 44212), a new pyrrolidone derivative, reveals potent activity in in vitro and in vivo models of epilepsy. J Neurol Sciences, 238(suppl 1), 2005, S133.
34. Margineanu, DG, Michel, Ph, Kenda, B, Matagne, A, Klitgaard, H, Seletracetam (ucb 44212), a new pyrrolidone derivative, inhibits epileptiform responses in hippocampal slices in vitro. Epilepsia, 46(suppl 6), 2005, 121.
35. +” rat hippocampal slice model. Epilepsia 47:suppl 3 (2006), 74–75.
36. Rigo, JM, Nguyen, L, Hans, G, et al. Seletracetam (ucb 44212): effect on inhibitory and excitatory neurotransmission. Epilepsia, 46(suppl 8), 2005, 110.
37. + currents in rat brain neurons in vitro. Epilepsia, 46(suppl 8), 2005, 116.
38. 2+] increase in rat cortical neurons in vitro. Epilepsia, 46(suppl 8), 2005, 119.